The HPV vaccine, first offered to girls in the UK in 2008 and later extended to boys, has driven a substantial fall in HPV infections and cervical cancer cases, addressing screening gaps.

Public health officials warn that maintaining vaccination uptake is crucial, as current rates—about 75% nationally and 60% in London—could translate into preventable deaths if they drop further.

Experts urge urgent action to reach communities with lower uptake and to integrate vaccination with cervical screening in pursuit of near-elimination goals.

Researchers credit high vaccine uptake for the decline, with approximately 90% vaccination in the studied cohort.

Beyond cervical cancer, the vaccine is reducing other HPV-related cancers and conditions, with early estimates suggesting around 200 lives saved so far and potentially up to 18,000 in the future.

The study reinforces continuing emphasis on HPV vaccination alongside cervical screening as core strategies to prevent cervical cancer in England.

Public health leaders, including NHS vaccination director Caroline Temmink, frame the vaccine as a tool toward eliminating cervical cancer as part of the NHS 2040 goal.

There is concern that post-COVID declines and uneven global uptake could affect future outcomes, though UK data show strong early benefits.

Analyses of English cancer mortality and vaccination data indicate that receiving the vaccine in early adolescence is linked to near-zero risk of dying from cervical cancer before age 30.

No cervical cancer deaths occurred among women aged 20 to 24 in England between 2020 and 2024 in the study.

Since vaccination began, the study estimates nearly 200 young women have avoided dying from cervical cancer.

The program targets year 8 students with some catch-up in years 9 and 10, and the vaccine also protects against several other cancers and genital conditions.